Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Theravance BiopharmaTBPH +0.12%72 PB Ratio is 2.99 as of Jul. 30, 2026, which is 1% above its 10-year median of 2.95. GuruFocus rates TBPH with a GF Score™ of 72/100 and a GF Value™ of $18.67 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,228 Biotechnology companies, Theravance Biopharma ranks worse than 53.91% on this metric.
The historical rank and industry rank for Theravance Biopharma's PB Ratio or its related term are showing as below:
TBPH'
s PB Ratio Range Over the Past 10 Years
Min: 1.38 Med: 2.95 Max: 52.36
Current: 2.99
During the past 13 years, Theravance Biopharma's highest PB Ratio was 52.36. The lowest was 1.38. And the median was 2.95.
TBPH's PB Ratio is ranked worse than 53.91% of 1228
companies
in the Biotechnology industry
Industry Median: 2.69
vs TBPH: 2.99
During the past 12 months, Theravance Biopharma's average Book Value Per Share Growth Rate was 69.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -5.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Theravance Biopharma was -5.00% per year. The lowest was -69.90% per year. And the median was -38.20% per year.
Back to Basics: PB Ratio
Theravance Biopharma (NAS:TBPH) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Theravance Biopharma PB Ratio Related Terms
Theravance Biopharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Theravance Biopharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Theravance Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theravance Biopharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Theravance Biopharma (TBPH) has a PB Ratio of 2.99 as of Jul. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Theravance Biopharma and its competitors. This is near median its historical median of 2.95. Over the past decade, Theravance Biopharma's PB Ratio has ranged from 1.38 to 52.36. According to the industry distribution chart, Theravance Biopharma ranks #662 out of 1228 companies in the Biotechnology industry, placing it in the top 53.9%.
Is Theravance Biopharma's PB Ratio too high?
Theravance Biopharma's current PB Ratio of 2.99 is near median its 10-year median of 2.95. Over the past 10 years, this metric has ranged from a low of 1.38 to a high of 52.36. The Biotechnology industry median PB Ratio is 2.69. Theravance Biopharma's value of 2.99 is 11.2% above this industry median. Based on the distribution chart, Theravance Biopharma ranks #662 out of 1228 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's PB Ratio compare to ABUS and SANA?
According to the Biotechnology industry distribution chart, Theravance Biopharma ranks #662 out of 1228 companies for PB Ratio. This places Theravance Biopharma in the lower half of its industry. The industry median PB Ratio is 2.69. Theravance Biopharma's value of 2.99 is 11.2% above this benchmark. Historically, Theravance Biopharma's own PB Ratio has ranged from 1.38 to 52.36 over the past decade. While the company's 10-year median is 2.95 vs. the industry median of 2.69, Theravance Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.69, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theravance Biopharma's current PB Ratio of 2.99 is 11.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Theravance Biopharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theravance Biopharma's current PB Ratio is 2.99, which is near median its own 10-year median of 2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (TBPH) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.67, compared to a current price of $16.87 — trading 9.6% below its estimated fair value. The current PB Ratio is 2.99, which is near median its 10-year median of 2.95 and 11.2% above the Biotechnology industry median of 2.69. Theravance Biopharma's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Theravance Biopharma (TBPH), the current PB Ratio is 2.99 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theravance Biopharma (TBPH) Overvalued in 2026?
Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued.
The current stock price of $16.87 is trading 9.6% below its estimated GF Value™ of $18.67.
GuruFocus considers Theravance Biopharma to be Modestly Undervalued.
Key valuation signals for TBPH:
PB Ratio: 2.99 (near median its 10-year median of 2.95)
GF Value™: $18.67 vs. price of $16.87 (9.6% below fair value)
Industry Position: 11.2% above the Biotechnology median (#662 of 1228)
No single metric tells the full story. See the TBPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score
Get the complete analysis for TBPH
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TBPH has been successfully added to your 
